ReviewFrontiers in endocrinology2025
Unraveling the metabolic pathways between atherosclerosis and sarcopenia.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Sebacic Acid: A Multifunctional Medium-Chain Dicarboxylic Acid in Metabolic Regulation and Tissue Regeneration.Current issues in molecular biology · 2026Review
- Article
- The association between sarcopenia and carotid artery plaque: a mediation analysis of inflammatory biomarkers.BMC endocrine disorders · 2026Article
- Beyond traditional lipid markers: low-density lipoprotein cholesterol with apolipoprotein B ratio - a novel biomarker for sarcopenia?Archives of medical science : AMS · 2026Article
- Functional training for sarcopenia in older adults: mechanisms, benefits, and clinical implications.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia and atherosclerosis are age-related conditions pathologically intertwined through a self-reinforcing, bidirectional cycle. This review dissects the core mechanistic pillars of this synergy such as insulin resistance, chronic low-grade inflammation, ectopic lipid deposition, and hormonal dysregulation. We detail how skeletal muscle dysfunction exacerbates systemic insulin resistance and inflammatory cascades that accelerate endothelial damage and atherogenesis. Conversely, atherosclerotic vascular impairment compromises microcirculatory function, inducing muscle ischemia and metabolic decline. Beyond pathogenesis, we evaluate integrated intervention, including combined exercise, anti-inflammatory diets, and pleiotropic pharmacotherapies, that concurrently target shared pathways in muscle and vasculature. By framing this comorbidity within the context of aging hallmarks, we advocate a paradigm shift from organ-specific management toward a holistic, geroscience-based approach to mitigate frailty and disability in the aging population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.